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CYLD Inhibits Melanoma Growth and Progression
through Suppression of the JNK/AP-1 and
b1-Integrin Signaling Pathways
Hengning Ke1, Christina K. Augustine2,3, Vineela D. Gandham1, Jane Y. Jin1, Douglas S. Tyler2,3,
Steven K. Akiyama4, Russell P. Hall1 and Jennifer Y. Zhang1
The molecular mechanisms mediating cylindromatosis (CYLD) tumor suppressor function appear to be
manifold. Here, we demonstrate that, in contrast to the increased levels of phosphorylated c-Jun NH2-terminal
kinase (pJNK), CYLD was decreased in a majority of the melanoma cell lines and tissues examined. Exogenous
expression of CYLD but not its catalytically deficient mutant markedly inhibited melanoma cell proliferation and
migration in vitro and subcutaneous tumor growth in vivo. In addition, the melanoma cells expressing
exogenous CYLD were unable to form pulmonary tumor nodules following tail-vein injection. At the molecular
level, CYLD decreased b1-integrin and inhibited pJNK induction by tumor necrosis factor-a or cell attachment to
collagen IV. Moreover, CYLD induced an array of other molecular changes associated with modulation of the
‘‘malignant’’ phenotype, including a decreased expression of cyclin D1, N-cadherin, and nuclear Bcl3, and an
increased expression of p53 and E-cadherin. Most interestingly, coexpression of the constitutively active MKK7
or c-Jun mutants with CYLD prevented the above molecular changes, and fully restored melanoma growth and
metastatic potential in vivo. Our findings demonstrate that the JNK/activator protein 1 signaling pathway
underlies the melanoma growth and metastasis that are associated with CYLD loss of function. Thus, restoration
of CYLD and inhibition of JNK and b1-integrin function represent potential therapeutic strategies for treatment
of malignant melanoma.
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INTRODUCTION
Melanoma represents the most deadly type of skin cancer
whose incidence has been on the rise worldwide at a rate
faster than most other cancers. In 2010, over 68,130 new
cases of invasive melanoma were diagnosed in the United
States alone, where B8,700 people die of this disease
annually (Linos et al., 2009; Alexandrescu et al., 2010).
Despite recent advances in this field, a cure for melanoma is
still beyond reach for many patients (Gray-Schopfer et al.,
2007). To understand better the molecular mechanisms
underlying melanoma pathogenesis and to shed light on
new therapeutic strategies, we focused on exploring how the
tumor suppressor cylindromatosis (CYLD) controls melanoma
cell growth and metastasis through the c-Jun NH2-terminal
kinase (JNK)/activator protein 1 (AP-1) and b1-integrin
signaling pathways.
CYLD was initially discovered as a tumor suppressor
owing to its dominant genetic linkage to cylindromas (Bignell
et al., 2000). Recent genetic and biomarker studies have
linked CYLD loss-of-function to a broad range of none-
pidermal cancers, including melanoma, myeloma, cervix,
colon, breast, liver, kidney, and prostate cancers (Strobel
et al., 2002; Hirai et al., 2004; Wang et al., 2005;
Hellerbrand et al., 2007; Jenner et al., 2007; Kikuno et al.,
2008; Hutti et al., 2009; Massoumi et al., 2009; Massoumi,
2011). Nevertheless, little is understood about the functional
importance and the nature of the molecular intricacies
between CYLD and its downstream targets in these cancers.
In normal cells, CYLD functions as a deubiquitinase that
preferentially removes the activating K63-linked polyubiqui-
tin chains from an array of target proteins involved in
signal transduction and gene regulation. Examples of CYLD
targets include TRAF2/6, Bcl3, plk1, Tak1, lck, HDAC6, and
Dvl (Wilkinson, 1997; Bignell et al., 2000; Brummelkamp
et al., 2003; Kovalenko et al., 2003; Regamey et al., 2003;
Trompouki et al., 2003; Reiley et al., 2004, 2006, 2007;
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Stegmeier et al., 2007). Downstream of TRAF2/6 are the
classical IkappaB kinase/NF-kB and JNK/AP-1 signaling
pathways, which are subject to additional controls by CYLD
at IkappaB kinaseg and AP-1 levels, respectively (Brummelk-
amp et al., 2003; Kovalenko et al., 2003; Regamey et al.,
2003; Trompouki et al., 2003; Reiley et al., 2004; Miliani de
Marval et al., 2011). Of particular relevance to melanoma,
the NF-kB pathway has an essential role in cell survival
and tissue invasion (Ueda and Richmond, 2006). Similarly,
Bcl3, a noncanonical NF-kB subunit, is activated in
response to CYLD downregulation by Snail1 and contributes
to the subsequent upregulation of N-cadherin and
cyclin D1 in melanoma cells (Massoumi et al., 2009). In
contrast, the role of the JNK/AP-1 signaling pathway in
melanoma is not well defined. Expression of the dominant
negative c-Jun or c-Fos mutant enhances melanoma
soft-agar colony formation, suggesting that AP-1 suppresses
melanoma growth (Huang et al., 2003; Yang et al., 2004). On
the other hand, elevated JNK/c-Jun signaling is characterized
as a central process in melanoma cells harboring an
hyperactive MEK-ERK signaling cascade (Lopez-Bergami
et al., 2007). In addition, JNK1 is involved in promoting cell
cycle progression or preventing apoptosis in various mela-
noma cell lines (Alexaki et al., 2008). These latter findings
suggest that the JNK/AP-1 pathway is important for melanoma
tumorigenesis.
In this study, we investigated the functional importance of
JNK/AP-1 in melanoma malignancy in response to CYLD gain
and loss of function. We demonstrated that CYLD was
significantly downregulated, whereas JNK activation was
increased in a majority of human melanoma tissues and cell
lines examined. Exogenous expression of CYLD inhibited
melanoma cell growth and migration in vitro. Consistently,
CYLD but not its catalytically deficient mutant inhibited
subcutaneous melanoma growth in immunodeficient mice,
which is accompanied by the downregulation of cyclin D1
and N-cadherin and the upregulation of E-cadherin and p53.
Moreover, CYLD downregulated the expression of the b1-
integrin and suppressed JNK activation during cell adhesion
to collagen IV. Both JNK/AP-1 and b1-integrin signaling
pathways were required for cell spreading and migration and
c-Jun was also required for upregulating b1-integrin expres-
sion. Most surprisingly, restoring JNK/AP-1 function by
expression of the constitutively active mutants of either MKK7
or c-Jun prevented CYLD effects on cyclin D1, p53, and
nuclear Bcl3. Consistently, cells transduced to coexpress CYLD
along with active MKK7 or c-Jun fully demonstrated the ability
to form tumor nodules in the lung when introduced through
tail-vein injection. Taken together, our findings indicate that
JNK/AP-1 underlies melanoma malignancy in lieu of CYLD
deficiency by acting upstream of b1-integrin and Bcl3.
RESULTS
CYLD is reduced, whereas pJNK is increased, in melanoma
We first examined the clinical relevance of CYLD to
melanoma by immunoblotting. We found that CYLD was
readily detectable in normal human melanocytes and skin
tissues but was significantly reduced in the melanoma cell
lines and tissues examined (Figure 1 and b). As the JNK
signaling pathway is among the downstream targets of CYLD
(Reiley et al., 2004; Miliani de Marval et al., 2011), we
predicted that JNK activation might be increased in these
melanoma samples. As expected, phosphorylated c-Jun NH2-
terminal kinase (pJNK) was expressed at higher levels in all
melanoma cell lines and tissues compared with that of the
normal melanocytes and skin tissues, respectively (Figure 1a
and b). Interestingly, pJNK was predominantly detected at the
p46 position, whereas the total JNK1 and JNK2 levels vary at
the p46 and p54 position between different melanoma cell
lines and tissue samples. Further JNK kinase analysis revealed
that JNK1 but not JNK2 activity was increased in a majority of
melanoma cell lines (Supplementary Figure S1a online).
These findings indicate that JNK1 is the predominant isoform
activated in melanoma cells, which is in agreement with the
data showing that JNK1 is essential for melanoma growth and
survival (Alexaki et al., 2008). Consistent with the increased
pJNK levels, p-c-Jun was readily detected in melanoma
tissues (Supplementary Figure S1b online). To determine
whether CYLD is downregulated at the transcriptional level,
we examined a previously generated gene array data set of
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Figure 1. Cylindromatosis (CYLD) is reduced, whereas phosphorylated c-Jun NH2-terminal kinase (pJNK) is increased, in melanoma. (a, b) Immunoblotting for
CYLD, pJNK, JNK1 and JNK2, and actin with protein lysates from (a) primary human melanocytes of passage 4 and 6 (Me1 and Me2) and melanoma cell lines,
including DM733, Skmel28, A375, A2058, DM598, and DM738, and (b) normal human skin (S1 and S2) and melanoma tissues (M1–M11). The relative
densitometry is shown below each p46 band of pJNK, with the values of Me1 and S1 set as 1.0.
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melanoma cell lines (GSE10916). This analysis revealed that
CYLD messenger RNA was nearly absent in over 90% of 50
melanoma cell lines examined. These data indicate that
CYLD is reduced at both protein and messenger RNA levels,
whereas JNK activation is increased in melanoma.
CYLD inhibits melanoma cell proliferation and migration
To examine how CYLD affects melanoma tumorigenesis, we
expressed LacZ control or CYLD in A2058 and SKmel28
human melanoma cell lines through retroviral gene transduc-
tion. Expression of CYLD inhibited cell proliferation in
monolayer cell culture and reduced the capacity of ancho-
rage-independent growth as assessed by soft-agar colony
formation (Figure 2a and b). In addition, CYLD substantially
slowed down scratch wounding–induced cell migration
(Figure 2c). These findings indicate that CYLD inhibits growth
and migration of melanoma cells.
CYLD inhibits melanoma growth and progression in vivo
To determine the in vivo growth effects of CYLD expression
in melanoma, we performed subcutaneous tumor growth
analysis with A2058 cells that have undergone gene
transduction for the expression of LacZ or CYLD. Cells
expressing CYLD displayed a reduced tumor growth kinetic
as compared with the control cells (Figure 3a). Consistently,
CYLD-expressing tumors had features of reduced cell
proliferation and enhanced cell apoptosis as indicated by
the decreased number of Ki-67-positive cells and the
increased number of caspase-3-positive cells, respectively
(Figure 3b and c, Supplementary Figure S2 online). In
contrast, tumors expressing catalytically deficient CYLD
mutant, CYLDm, (CYLD.754), a catalytically deficient C-
terminal deletion mutant of CYLD, had an increased number
of Ki-67-positive cells and a reduced number of caspase-3-
positive cells (Figure 3a–c, Supplementary Figure S2 online).
In addition, E-cadherin—an epithelial cell marker—was
increased, whereas N-cadherin—a mesenchymal cell mar-
ker—was reduced, in tumors expressing CYLD but not
CYLDm (Figure 3c). These data indicate that CYLD but not
CYLDm inhibits melanoma growth and progression.
b1-Integrin and pJNK are downregulated by CYLD and display
cross talk
To explore how CYLD inhibits invasive tumor growth, we
examined the expression status of b1-integrin, which is a
member of the heterodimeric transmembrane receptors
involved in melanoma migration and chemotaxis (Hodgson
and Dong, 2001; Hegerfeldt et al., 2002). Immunoblotting
revealed that b1-integrin was highly expressed in melanoma
cell lines and tissues (Supplementary Figure S3 online).
Exogenous expression of CYLD downregulated b1-integrin
at both protein and messenger RNA levels as shown by
reverse transcriptase–PCR (RT-PCR) and immunoblotting,
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Figure 2. Cylindromatosis (CYLD) inhibits melanoma cell growth, colony formation, and migration. (a) Monolayer cell growth, (b) soft-agar colony formation,
and (c) scratch-wounding assay. Malignant A2058 and SKmel28 human melanoma cell lines were transduced with retrovirus encoding LacZ or CYLD and
then used for growth and wounding assays. Efficiency of gene transduction was confirmed by immunoblotting for CYLD with actin for control. Representative
data of triplicate experiments were shown in the graphs as average numbers of (a) cell number or (b) soft-agar colonies ±SD. For scratch-wounding assay,
cells were serum starved for 16 hours and then scratch wounded. Images were taken at 0 and 24 hours post wounding. Bar¼200 mm.
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respectively (Figure 4a). Consistently, subcutaneous tumors
expressing CYLD, but not those expressing CYLDm, ex-
pressed a significantly reduced level of b1-integrin as shown
by immunostaining (Figure 4a). Further in line with these
data, CYLD inhibited pJNK induction not only by tumor
necrosis factor-a (TNFa) but also by cell adhesion to collagen
IV, a natural substrate and activator of b1-integrin (Figure 4b).
On the other hand, siRNA-mediated gene silencing of c-Jun
markedly decreased b1-integrin (Supplementary Figure S4a
online), indicating that the JNK downstream target AP1 is
required for the expression of b1-integrin. Similarly, pharma-
cological JNK-specific inhibition with BI-78D3 prevented b1-
integrin induction by 12-o-tetradecanoylphorbol-13-acetate
(Supplementary Figure S4b online). These data indicate that
the JNK/AP-1 and b1-integrin signaling pathways can cross
talk and are negatively regulated by CYLD. Interestingly, JNK
inhibition induced a minimal effect on the expression levels
of CYLD (Supplementary Figure S4c online), implicating that
JNK function is not directly involved in regulating CYLD
expression.
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Figure 3. Cylindromatosis (CYLD) inhibits melanoma growth in vivo. (a) Subcutaneous tumor growth kinetics. A2058 cells transduced to express LacZ, CYLD,
or catalytically deficient CYLD mutant (CYLDm) were injected subcutaneously into immunodeficient nude mice (2 106 cells in 200ml phosphate-buffered
saline (PBS) per mouse). Graph represents the average tumor volume of 4–8 mice ±SD per group. Expression of CYLD and CYLDm was confirmed by
immunoblotting for CYLD and actin. (b, c) Histological analysis of the 4-week-old subcutaneous tumors by hematoxylin and eosin (H&E) staining and
immunostaining for Ki-67, E-cadherin, or N-cadherin (orange), and nuclei (blue). Bar¼ 100mm.
224 Journal of Investigative Dermatology (2013), Volume 133
H Ke et al.
JNK/AP-1 and b1-Integrin Underlie Melanoma Malignancy
b1-Integrin and pJNK are essential for melanoma cell
attachment and migration
The functional link between b1-integrin and JNK in melano-
ma cell lines was next tested via cell attachment and
migration assays. As expected from the previous studies
(Fogerty et al., 1990), b1-integrin inhibition with the
neutralizing mAb mAb13 inhibited cell attachment, as was
observed for pharmacological JNK inhibition with BI-78D3
(Figure 4c). Conversely, activation of b1-integrin with the
mAb 12G10 enhanced cell attachment, which was abolished
by the presence of BI-78D3 (Figure 4d). Scratch-wounding
assay revealed that mAb13 and the JNK inhibitors BI-78D3
and SP600125 inhibited cell migration. These findings
indicate that JNK function is essential for b1-integrin-
mediated cell attachment and migration (Figure 4e). Taken
together, these data underscore an important regulatory loop
between JNK and b1-integrin in melanoma.
JNK/AP-1 activation restores normal expression of cyclin D1
and p53
To determine whether JNK suppression is important for CYLD
inhibition of melanoma tumorigenesis, we expressed CYLD
with or without the constitutively active mutants of c-Jun or
MKK7, an immediate upstream activator of JNK. Expression
of CYLD alone resulted in a downregulation of cyclin D1
both at the basal state and upon cell cycle reentry following
starvation. Surprisingly, coexpression of either MKK7 or c-Jun
with CYLD restored normal expression of cyclin D1 (Figure 5).
In addition, CYLD upregulated p53 by about 2-fold, which
was diminished by c-Jun and MKK7 (Figure 5). These findings
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Figure 4. Cylindromatosis (CYLD) downregulates b1-integrin and phosphorylated c-Jun NH2-terminal kinase (pJNK), both of which are required for cell
adhesion and migration. (a) b1-Integrin expression by immunoblotting, reverse transcriptase–PCR (RT-PCR), and immunostaining. Protein and RNA samples
were collected from A2058 cells at 48 hours post transduction and were analyzed by immunoblotting for b1-integrin, CYLD, and actin, and by RT-PCR for b1-
integrin and 18S RNA for control. The relative densitometry was shown below each b1-integrin band. The relative messenger RNA (mRNA) fold changes±SD
shown in the graph represent data from duplicate experiments. A P-value of o0.04 is shown in the graph. Immunostaining was performed with subcutaneous
tumors generated with transduced A2058 cells. Green: b1-integrin; blue: nuclei. (b) Immunoblotting for phosphorylated c-Jun NH2-terminal kinase (pJNK),
JNK1, JNK2, and actin. A2058 cells were treated with or without 50 ngml1 tumor necrosis factor-a (TNFa) or plated onto the collagen IV–coated dishes and
then collected at 15-minutes, 30-minutes, and 1-hour time points for protein analysis. (c, d) Cell attachment. A2058 cells were plated onto (c) collagen IV–coated
dishes in the presence of DMSO, 20 mgml1 mab13, or 10 mM BI-78D3 and imaged 1 hour later, or (d) plain culture dishes in the presence of 20 mgml1 12G10
along with or without 10mM BI-78D3 and imaged 3 hours later. (e) Cell migration. Near-confluent A2058 cell cultures were serum starved for 16 hours and then
scratch wounded in the presence of the indicated reagents. Images were taken imaged at 16 hours post wounding. Z, LacZ. (a) Bar¼ 100mm; (c, d) bar¼ 50 mm;
and (e) bar¼ 200mm.
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indicate that JNK/AP-1 is sufficient to overcome CYLD effects
on cyclin D1 and p53.
Activation of JNK/AP-1 restores melanoma growth and
metastatic potential
To further validate the functional importance of JNK/AP-1, we
introduced A2058 cells that had undergone various gene
transductions into immunodeficient nude mice through tail-
vein injection. At 8 weeks post injection, animals were killed
for pulmonary tumor growth analysis. We found that none of
the seven (0/7) animals injected with A2058-CYLD cells
developed visible melanoma nodules in the lung tissue. In
contrast, apparent pulmonary nodules were observed in 6/11,
4/5, 5/7, and 6/7 animals injected with cells expressing LacZ,
c-Jun, or CYLD together with MKK7 or c-Jun, respectively
(Table 1). These tumor nodules were confirmed to be of
melanoma origin as indicated by the dark and compact
histological appearance of the tumor islands and the positive
detection of Mart1, a melanocyte-specific marker (Figure 6a
and b). Expression of CYLD, c-Jun, and MKK7 were validated
by immunostaining of the respective tumor tissues (Figure
6b). Thus, JNK/AP-1 induction is sufficient to overcome
CYLD inhibition of melanoma progression. In agreement with
the gain-of-function effects, pharmacological JNK inhibition
with BI-78D3 markedly reduced the capacity of anchorage-
independent cell proliferation of A2058 cells, as demon-
strated by soft-agar colony formation analysis (Supplementary
Figure S5 online). Taken together, our findings indicate that
the JNK/AP-1 has a dominant role in tumorigenesis and
represents a potential therapeutic target for melanoma.
Bcl3, an NF-kB family transcription factor whose nuclear
translocalization is subject to negative regulation by CYLD,
has been previously characterized as a key oncogenic
effector and inducer of cyclin D1 in response to CYLD loss
of function (Massoumi et al., 2006, 2009). As expected, Bcl3
was predominantly detected in the nuclear of the subcuta-
neous tumor cells generated with A2058-LacZ control cells;
expression of CYLD resulted in the cytoplasmic presence of
Bcl3 (Supplementary Figure S6 online). Interestingly, coex-
pression of MKK7 and CYLD restored the nuclear presence of
Bcl3 in melanoma tissues (Supplementary Figure S6 online).
These results implicate that JNK/AP-1 function acts upstream
of Bcl3 to overcome CYLD inhibition of tumorigenesis.
DISCUSSION
We have shown that CYLD loss of function and JNK activation
are clinically relevant in all melanoma tissues and cell lines
examined. Restoring CYLD expression not only retards
melanoma growth in vitro and in vivo but also markedly
diminishes melanoma metastatic potential in vivo. Most
importantly, we have established a mechanistic link between
CYLD deficiency and JNK/AP-1 activation by characterizing
JNK/AP-1 as critical effectors acting downstream of CYLD and
upstream of b1-integrin. In addition, we have demonstrated
that JNK/AP-1 can cross talk with the b1-integrin signaling
pathway in response to altered CYLD function.
JNK/AP-1 proteins are involved in regulating an array of
cellular processes, including cell proliferation, migration, and
survival, and are indispensable for epidermal cancers (Zhang
et al., 2007; Ke et al., 2010; Jin et al., 2011; Miliani de Marval
et al., 2011). In this study, we have shown that JNK/AP-1 is
subject to CYLD control and its deregulation promotes
melanoma tumorigenesis. In response to CYLD loss of
function, JNK/AP-1 remains constitutively active, leading to
the increased expression of the N-cadherin and cyclin D1
and the reduced expression of p53 tumor suppressor. We
have also demonstrated that JNK/AP-1 is able to overcome
CYLD blockade of Bcl3 nuclear entry. However, our findings
do not exclude the possibility of a synergistic effect between
JNK/AP-1 and Bcl3 in inducing other target genes. In this
regard, it has been previously shown that Bcl3 interacts with
c-Jun and c-Fos in fibroblast and HeLa cells, thereby
potentiating AP-1 induction of cell proliferation (Na et al.,
1999). Presumably, the physical interaction between AP1 and
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Table 1. MKK7 or c-Jun can overcome CYLD-
inhibition of intravenous melanoma growth
Transduced
genes
Total number of mice for tail-
vein injection
Number of mice with
lung tumor
LacZ 11 6
CYLD 7 0
CYLD + c-Jun 7 6
CYLD +
MKK7
7 5
c-Jun 5 4
Abbreviation: CYLD, cylindromatosis.
JNK/AP-1 activation retores melanoma growth potential.
A2058 cells were transduced for expression of LacZ, CYLD, c-Jun, or
CYLD together with c-Jun or MKK7 and then injected into immunodefi-
cient nude mice through tail vein. Animals were killed at 8 wks following
cell injection. The two-tailed t-test P-values werep0.03 as obtained with
Microsoft Excel.
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Bcl3 facilitates Bcl3-nuclei entry upon AP1 activation. It will
be of great interest to characterize the nature of potential
cross talk between Bcl3 and JNK/AP-1 signaling pathways in
melanoma.
Integrin family receptors have been implicated as feasible
therapeutic targets owing to their cell surface localization and
their role in controlling melanocyte adhesion, migration, and
proliferation (Pinon and Wehrle-Haller, 2010; Juliano et al.,
2011). We showed that CYLD downregulated b1-integrin at a
transcriptional level via suppression of AP-1 function.
Blocking b1-integrin through an antibody-mediated approach
in turn dampened JNK signaling in response to cell–substrate
attachment. Moreover, inhibition of either JNK or b1-integrin
function impaired cell adhesion and migration. These
findings indicate that JNK and b1-integrin signaling pathways
function in a regulatory loop to mediate cell migration. It is
intriguing to point out that the role of b1-integrin in
melanoma is rather complex owing to the complexity of
heterodimerization with the a-integrin subunits (Nakahara
et al., 1996; Ziober et al., 1999). Future efforts may be
directed to further characterize the CYLD effects on the
dynamics of b1-integrin heterodimerization and the function
of other integrin subunits in melanoma.
In summary, our findings establish that CYLD deficiency
has a wide clinical relevance to melanoma and that the JNK/
AP-1 signaling pathway underlies melanoma malignancy.
These findings underscore the potential of new therapeutic
strategies, including approaches to restore CYLD expression
and to inhibit the JNK/AP-1 and b1-integrin signaling
pathways in melanoma.
MATERIALS AND METHODS
Reagents, cell culture, and gene transduction
Cell culture media and secondary antibodies were purchased from
Invitrogen (Carlsbad, CA) and primary antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA) unless otherwise noted. Human
LacZ
H&E
Mart1
c-Jun
CYLD
MKK7
b
a CYLD + c-JunCYLD CYLD + MKK7
Figure 6. c-Jun NH2-terminal kinase (JNK)/activator protein 1 (AP-1) activation restores melanoma malignancy. (a) Hematoxylin and eosin (H&E) staining of
the pulmonary tissues collected from nude mice at 8 weeks post intravenous injection of A2058 cells. (b) Immunostaining of the pulmonary tumor nodules.
Orange: Mart 1, c-Jun; green: cylindromatosis (CYLD), MKK7; blue: nuclei. Note that melanoma clusters were present in the lungs of animals injected with cells
expressing LacZ or CYLD together with MKK7 or c-Jun but not CYLD alone. Bar¼ 100 mm.
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melanoma cell lines, including A2058, SKmel28, and A375, were
obtained from ATCC (Manassas, VA). DM733, DM598, DM738, and
DM833 were kindly provided by Dr Hilliard Seigler (Duke University
Medical Center), and were derived from primary biopsies of metastatic
melanoma obtained under a protocol approved by the Duke
University Institutional Review Board. All cell lines were cultured
with 10% fetal bovine serum/DMEM and were not authenticated in
this study other than the observation of melanin expression. Primary
human melanocytes were isolated from neonatal foreskin and cultured
in M-254 media. Retroviruses encoding LacZ, CYLD, CYLD.754,
MKK7, or c-Jun were packaged in 293T phoenix cells as described in
previous studies (Zhang et al., 2007; Ke et al., 2010; Jin et al., 2011;
Miliani de Marval et al., 2011). For gene transduction, melanoma cell
cultures were pretreated with 8mgml1 polybrene for 15minutes and
then fed with retroviral media supplemented with 8mgml1 polybrene.
Cell culture plates were spun at 500g for 1hour in a prewarmed (32 1C)
Beckman centrifuge (Brea, CA) and then incubated for another 3hours
at a tissue culture incubator before media replacement. Multiplex
gene transduction was performed at 16-hour intervals.
Cell growth, adhesion, scratch-wounding, and soft-agar
formation analysis
Cells (5 104) transduced as above were plated in triplicates onto
35-mm dishes and trypsinized for counting at days 1, 2, and 3. For
cell attachment and spreading assays, cells are plated along with
DMSO solvent, the JNK inhibitors (10 mM BI78D3 or SP600125,
Sigma-Aldrich, St. Louis, MO), or 20 mgml1 mAb13 or 12G10
monoclonal antibodies against b1-integrin (Fogerty et al., 1990;
Mould et al., 1995). Images were taken 1 hour after plating. Soft-agar
formation and scratch-wounding analysis were performed as
described previously (Ke et al., 2010; Miliani de Marval et al., 2011).
Animal studies
Animal studies were conducted in accordance with protocols
approved by the Duke Animal Care and Use Committee. Immuno-
deficient athymic NCr-nu/nu mice (nX4 per group) were purchased
from Duke animal facility (Durham, NC). For subcutaneous tumor
growth, A2058 cells were harvested at day 2 after gene transduction
and suspended (2 106 cells per 200 ml phosphate-buffered saline)
for each injection. Tumors were measured weekly for 4 weeks and
then collected from euthanized animals. For tail-vein injection, cells
were suspended at a density of 1 106 per 100ml phosphate-
buffered saline for each mouse. Animals were killed for pulmonary
tumor growth analysis eight weeks later.
Real-time RT-PCR
Total RNA was isolated from melanoma cells transduced for
expression of LacZ or CYLD using Qiagen RNA-isolation kit
(Valencia, CA). Standard real-time RT-PCR for b1-integrin was
performed with the forward 50-TTTCGATGCCATCATGCAA-30 and
reverse 50-ACCAGCAGCCGTGTAACATTC-30 primers. RT-PCR for
18S RNA was performed as a control with the forward 50-TCTCCG
GAATCGAACCCTGATT-30 and reverse 50-CCCATTCGAACGTCTG
CCCTATC-30 primers.
Immunoblotting
Human foreskin and primary melanoma tissues were obtained from
Duke Hospital in accordance with an approved institutional review
board protocol. Tissue lysates were prepared with radioimmuno
precipitation assay buffer using a bullet blender (Next Advance,
Averill Park, NY). Protein lysates (20 mg each) of tissues or cultured
cells were analyzed by immunoblotting with antibodies against
CYLD(H-419), p-JNK(G7), JNK1(F-3), JNK2(N-18), and actin (Santa
Cruz Biotechnology), followed by Alexa IRDye-conjugated second-
ary antibodies (Invitrogen, Grand Island, NY). For b1-integrin blots,
protein lysates were prepared and analyzed in the absence of
dithiothreitol and blotted with the 12G10 mAb. Subcellular
fractionation was performed as described (Ke et al., 2010), and the
cytoplasmic and nuclear fractions were analyzed by immunoblotting
with antibodies against Bcl3, c-Jun, actin, and lamin A/C (GenScript
USA, Piscataway, NJ).
Histological analysis
Hematoxylin and eosin staining was performed with paraffin
sections by the Duke Pathology lab (Durham, NC). Immunostaining
was performed with frozen tissue sections as previously described
(Zhang et al., 2007; Ke et al., 2010). Fluorescent pictures were taken
and processed using the Olympus BX41 microscopic imaging system
(Center Valley, PA).
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